Free Trial

Compugen Q4 2024 Earnings Report

Compugen logo
$1.41 -0.05 (-3.42%)
As of 04:00 PM Eastern

Compugen EPS Results

Actual EPS
-$0.07
Consensus EPS
$0.07
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

Compugen Revenue Results

Actual Revenue
$1.47 million
Expected Revenue
$17.47 million
Beat/Miss
Missed by -$16.00 million
YoY Revenue Growth
N/A

Compugen Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Remove Ads

Compugen Earnings Headlines

Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Compugen reports Q4 EPS (7c) vs. 11c last year
See More Compugen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Compugen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compugen and other key companies, straight to your email.

About Compugen

Compugen (NASDAQ:CGEN), a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

View Compugen Profile

More Earnings Resources from MarketBeat